Julie Brevard

934 total citations
18 papers, 512 citations indexed

About

Julie Brevard is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Julie Brevard has authored 18 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 5 papers in Hematology and 4 papers in Immunology. Recurrent topics in Julie Brevard's work include Acute Myeloid Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Hemoglobinopathies and Related Disorders (3 papers). Julie Brevard is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Hemoglobinopathies and Related Disorders (3 papers). Julie Brevard collaborates with scholars based in United States, Australia and United Kingdom. Julie Brevard's co-authors include Sarah Lord, Simon H. Budman, Emil Chiauzzi, Patrick Kelly, Robert D. Arbeit, Nathaniel P. Katz, Timothy J. Sullivan, Errol P. Prens, Egilius L.H. Spierings and Erica S. Klaassen and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Neuro-Oncology.

In The Last Decade

Julie Brevard

18 papers receiving 496 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julie Brevard United States 11 111 96 80 77 68 18 512
Nicolas Batty United States 9 225 2.0× 151 1.6× 68 0.8× 57 0.7× 102 1.5× 18 744
Qiao Chu China 15 140 1.3× 70 0.7× 38 0.5× 29 0.4× 112 1.6× 39 829
Victoria Goldberg Argentina 12 176 1.6× 106 1.1× 52 0.7× 56 0.7× 49 0.7× 22 707
Rahul Suresh United States 10 152 1.4× 91 0.9× 24 0.3× 79 1.0× 29 0.4× 19 472
Fangping Chen China 18 368 3.3× 294 3.1× 97 1.2× 158 2.1× 62 0.9× 50 1.2k
Federica Ricci Italy 12 111 1.0× 162 1.7× 53 0.7× 38 0.5× 32 0.5× 51 522
Megan N. Perez United States 13 58 0.5× 152 1.6× 22 0.3× 101 1.3× 61 0.9× 23 593
Babak Nejati Iran 11 74 0.7× 48 0.5× 16 0.2× 47 0.6× 27 0.4× 25 351
Ville Autio Finland 18 274 2.5× 78 0.8× 69 0.9× 58 0.8× 51 0.8× 26 999
Fenglan Lou China 18 149 1.3× 278 2.9× 112 1.4× 45 0.6× 88 1.3× 34 1000

Countries citing papers authored by Julie Brevard

Since Specialization
Citations

This map shows the geographic impact of Julie Brevard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Brevard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Brevard more than expected).

Fields of papers citing papers by Julie Brevard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Brevard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Brevard. The network helps show where Julie Brevard may publish in the future.

Co-authorship network of co-authors of Julie Brevard

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Brevard. A scholar is included among the top collaborators of Julie Brevard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Brevard. Julie Brevard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
3.
Fuente, Macarena I. de la, Howard Colman, Mark Rosenthal, et al.. (2022). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-Oncology. 25(1). 146–156. 52 indexed citations
4.
Lal, Ashutosh, R. Clark Brown, Thomas D. Coates, et al.. (2021). Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. Blood. 138(Supplement 1). 4162–4162. 2 indexed citations
5.
6.
Wood, Kenneth W., James Geib, Eric Wu, et al.. (2020). An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood. 136(Supplement 1). 19–20. 4 indexed citations
7.
Young, Damon, Michael Popiolek, Patrick Trapa, et al.. (2020). D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited Dyskinesia Side Effects. ACS Chemical Neuroscience. 11(4). 560–566. 18 indexed citations
8.
9.
Cortes, Jörge E., Eunice S. Wang, Justin M. Watts, et al.. (2019). Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine. Blood. 134(Supplement_1). 674–674. 16 indexed citations
10.
Fuente, Macarena I. de la, Howard Colman, Mark Rosenthal, et al.. (2019). ACTR-52. PHASE 1 STUDY OF FT-2102, AN INHIBITOR OF MUTANT IDH1, IN PATIENTS WITH RELAPSED/REFRACTORY IDH1 MUTANT GLIOMAS: PRELIMINARY SAFETY AND CLINICAL ACTIVITY. Neuro-Oncology. 21(Supplement_6). vi25–vi25. 1 indexed citations
11.
12.
Balak, Deepak M.W., Martijn B. A. van Doorn, Robert D. Arbeit, et al.. (2016). IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clinical Immunology. 174. 63–72. 75 indexed citations
13.
Gordon, Patrick, Robert G. Cooper, Hector Chinoy, et al.. (2016). AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis. Annals of the Rheumatic Diseases. 75. 1119–1119. 5 indexed citations
14.
Thomas, Sheeba K., Wael A. Harb, J. Thaddeus Beck, et al.. (2015). Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. Blood. 126(23). 1540–1540. 10 indexed citations
15.
16.
Lord, Sarah, Julie Brevard, & Simon H. Budman. (2010). Connecting to Young Adults: An Online Social Network Survey of Beliefs and Attitudes Associated With Prescription Opioid Misuse Among College Students. Substance Use & Misuse. 46(1). 66–76. 116 indexed citations
17.
Chiauzzi, Emil, et al.. (2008). MyStudentBody–Stress: An Online Stress Management Intervention for College Students. Journal of Health Communication. 13(6). 555–572. 94 indexed citations
18.
Spierings, Egilius L.H., Julie Brevard, & Nathaniel P. Katz. (2008). Two-Minute Skin Anesthesia Through Ultrasound Pretreatment and Iontophoretic Delivery of a Topical Anesthetic: A Feasibility Study. Pain Medicine. 9(1). 55–59. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Batty Breakdown of academic impact, for papers by Qiao Chu Breakdown of academic impact, for papers by Victoria Goldberg Breakdown of academic impact, for papers by Rahul Suresh Breakdown of academic impact, for papers by Fangping Chen Breakdown of academic impact, for papers by Federica Ricci Breakdown of academic impact, for papers by Megan N. Perez Breakdown of academic impact, for papers by Babak Nejati Breakdown of academic impact, for papers by Ville Autio Breakdown of academic impact, for papers by Fenglan Lou
Rankless by CCL
2026